Pyxis Oncology (PYXS) Competitors $2.62 +0.15 (+5.87%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. ORGO, CMPX, BCYC, PRTA, RGNX, SLDB, CTMX, FULC, INBX, and MNPRShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Organogenesis (ORGO), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Prothena (PRTA), REGENXBIO (RGNX), Solid Biosciences (SLDB), CytomX Therapeutics (CTMX), Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Organogenesis Compass Therapeutics Bicycle Therapeutics Prothena REGENXBIO Solid Biosciences CytomX Therapeutics Fulcrum Therapeutics Inhibrx Biosciences Monopar Therapeutics Organogenesis (NASDAQ:ORGO) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Do institutionals and insiders believe in ORGO or PYXS? 49.6% of Organogenesis shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 33.0% of Organogenesis shares are held by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to ORGO or PYXS? In the previous week, Pyxis Oncology had 2 more articles in the media than Organogenesis. MarketBeat recorded 4 mentions for Pyxis Oncology and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.88 beat Pyxis Oncology's score of 0.11 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ORGO or PYXS? Organogenesis currently has a consensus price target of $7.33, indicating a potential upside of 79.69%. Pyxis Oncology has a consensus price target of $7.75, indicating a potential upside of 190.70%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Pyxis Oncology 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Which has stronger valuation and earnings, ORGO or PYXS? Organogenesis has higher revenue and earnings than Pyxis Oncology. Organogenesis is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$429.31M1.21$860K-$0.14-29.15Pyxis Oncology$16.15M10.24-$77.33M-$1.60-1.67 Is ORGO or PYXS more profitable? Pyxis Oncology has a net margin of 0.00% compared to Organogenesis' net margin of -1.92%. Organogenesis' return on equity of -0.37% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.92% -0.37% -0.20% Pyxis Oncology N/A -68.56%-52.14% Which has more volatility and risk, ORGO or PYXS? Organogenesis has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. SummaryOrganogenesis beats Pyxis Oncology on 9 of the 16 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.90M$2.63B$6.13B$10.51BDividend YieldN/A53.56%5.51%4.67%P/E Ratio-1.6724.0385.5226.80Price / Sales10.24603.97585.10183.02Price / CashN/A28.3526.3031.10Price / Book1.315.4713.166.63Net Income-$77.33M$32.78M$3.30B$276.44M7 Day Performance20.09%3.76%4.71%2.93%1 Month Performance39.58%9.35%8.36%9.95%1 Year Performance-21.59%-2.44%87.42%39.62% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology1.8563 of 5 stars$2.62+5.9%$7.75+196.4%-30.2%$163.30M$16.15M-1.6560Gap UpORGOOrganogenesis3.7966 of 5 stars$4.26+3.9%$7.33+72.1%+36.4%$520.12M$482.04M-30.43950CMPXCompass Therapeutics2.6759 of 5 stars$3.82+2.1%$13.88+263.2%+90.2%$517.18MN/A-8.4920News CoveragePositive NewsAnalyst ForecastBCYCBicycle Therapeutics4.0307 of 5 stars$7.61+2.8%$22.22+192.0%-65.1%$512.87M$35.28M-2.17240Trending NewsGap UpPRTAProthena3.0516 of 5 stars$9.76+3.7%$19.75+102.4%-41.5%$506.54M$10.34M-1.73130Analyst ForecastGap UpRGNXREGENXBIO4.5067 of 5 stars$9.85+2.1%$28.38+188.1%+10.0%$487.46M$83.33M-2.86370News CoverageAnalyst ForecastSLDBSolid Biosciences2.8642 of 5 stars$5.97-2.9%$15.00+151.3%-16.7%$478.89M$8.09M-2.13100Positive NewsCTMXCytomX Therapeutics4.145 of 5 stars$3.23+11.4%$5.42+67.7%+185.2%$478.25M$138.10M5.77170FULCFulcrum Therapeutics0.7988 of 5 stars$8.67-1.9%$9.60+10.7%+148.7%$478.17M$80M-7.11100Positive NewsINBXInhibrx Biosciences1.6054 of 5 stars$32.31-1.1%N/A+136.9%$473.38M$200K-3.05166Positive NewsMNPRMonopar Therapeutics1.7496 of 5 stars$75.90-1.0%$86.22+13.6%+2,058.4%$472.80MN/A-22.7910Analyst ForecastGap Up Related Companies and Tools Related Companies ORGO Alternatives CMPX Alternatives BCYC Alternatives PRTA Alternatives RGNX Alternatives SLDB Alternatives CTMX Alternatives FULC Alternatives INBX Alternatives MNPR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
